The frequency of metabolic syndrome in schizoprenia patients using antipsychotic medication and related factors Antipsikotik kullanan şizofreni hastalarında metabolik sendrom sıklıǧı ve ilişkili etmenleri
Yeni Symposium, cilt.49, sa.2, ss.67-76, 2011 (Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 49 Sayı: 2
- Basım Tarihi: 2011
- Dergi Adı: Yeni Symposium
- Derginin Tarandığı İndeksler: Scopus
- Sayfa Sayıları: ss.67-76
- Anahtar Kelimeler: Antipsychotics, Metabolic syndrome, Schizophrenia
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Objective: To investigate the prevalence of metabolic syndrome and related factors in outpatients with schizophrenia who are receiving antipsychotics and to compare schizophrenic patients with the healthy subjects in terms of metabolic syndrome. Methods: 162 out of 187 patients aged 20-56, admitted to psychiatric outpatient clinics in the Bakirkoy Research and Training Hospital for Psychiatric and Neurological Diseases and diagnosed as schizophrenia according to DSM-IV criteria have been enrolled. 25 patients excluded from the trial for refusing to give blood samples for the laboratory investigation. 56 healthy staff members have agreed to participate in the study as the control group. Şndings: The prevalence of metabolic syndrome in patients increased progressively as we used the Third Adult Treatment Panel [ATP III], ATP III-A, and the IDF criteria, with values of 32.1%, 35.8% and 42.0% respectively; whereas the prevalence of metabolic syndrome in the control group revealed rates of 5.4%, 5.4% and 7.1% with ATP III, ATP III-A, and the IDF criteria respectively. Metabolic syndrome was seen more commonly among female patients than male patients with schizophrenia, for each of the three diagnostic criteria. For both patients and the control group, the rate of metabolic syndrome increased with increasing age. The average age and duration of illness were higher in patients with metabolic syndrome than those without, for all diagnostic criteria. Among the antipsychotic drugs, the difference was not signiŞcant in terms of prevalence of metabolic syndrome. Low levels of HDL-cholesterol and high waist circumference were the most commonly seen criteria for metabolic syndrome, whereas the least commonly seen positive parameter was high levels of FPG (fasting plasma glucose) in both patients and the control group. Discussion and Conclusion: Metabolic syndrome in patients with schizophrenia is signiŞcantly more common than the healthy control group. The prevalence of metabolic syndrome according to ATP III in patients group shows similarity with previous studies. Concerning the risks for metabolic courses in schizophrenic patients, clinicans should evaluate the metabolic states of the patients in their routine follow-up. High waist circumference and low levels of HDL-cholesterol are probably the most important determinants of metabolic syndrome.